
Immunocore Holdings (IMCR) Stock Forecast & Price Target
Immunocore Holdings (IMCR) Analyst Ratings
Bulls say
Immunocore Holdings PLC is experiencing a robust commercial trajectory driven by its main product, KIMMTRAK, which has consistently surpassed quarterly sales expectations since its launch in early 2022. The company has significant growth potential in both U.S. and international markets, with increased penetration in community settings and anticipated additional drug launches abroad. Furthermore, the company's expanding pipeline, including various candidates targeting oncology, infectious, and autoimmune diseases, positions Immunocore favorably for future revenue streams and market expansion.
Bears say
Immunocore Holdings is facing a negative outlook primarily due to disappointing clinical data disclosures, which revealed low overall response rates (11% for melanoma and 6% for ovarian cancer) that fell short of market expectations. Furthermore, the company’s leading product, KIMMTRAK, is at risk from emerging competition, particularly IDYA's darovasertib, which may significantly impact its market share within the HLA-A2+ uveal melanoma segment. Additionally, the company is exposed to various downside risks, including potential setbacks in research and development, the emergence of new competitors, and prospects of dilutive financing.
This aggregate rating is based on analysts' research of Immunocore Holdings and is not a guaranteed prediction by Public.com or investment advice.
Immunocore Holdings (IMCR) Analyst Forecast & Price Prediction
Start investing in Immunocore Holdings (IMCR)
Order type
Buy in
Order amount
Est. shares
0 shares